FDA lifts a hold on a No­var­tis hear­ing loss drug, and tiny Gen­Vec gets a lift

Back in ear­ly Jan­u­ary, the strug­gling pen­ny stock biotech Gen­Vec $GN­VC post­ed a no­tice with the SEC that its part­ner No­var­tis had paused their study on a part­nered hear­ing loss drug so the phar­ma gi­ant could re­view safe­ty da­ta.

This morn­ing we found out that there was a clin­i­cal hold on the ear­ly-stage pro­gram, which has now been lift­ed by the FDA. But there’s no ex­pla­na­tion for what trig­gered the hold.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER